Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 2/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | UBE2N | P61088 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | HPN | P05981 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | ACACA | Q13085 | 2/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23459076 | 1.00 | CACNA1H (0.51) | CACNA1HCACNA1BCACNA1CSMN1; SMN2BCHE | |
| SCHEMBL15584882 | 0.86 | CACNA1H (0.53) | CACNA1HCACNA1BCACNA1CSMN1; SMN2BCHE | |
| SCHEMBL19494569 | 0.85 | SMN1; SMN2 (0.62) | CACNA1HCACNA1BCACNA1CSMN1; SMN2BCHE | |
| SCHEMBL23482086 | 0.84 | TUBB4A (0.51) | CACNA1HSMN1; SMN2CACNA1GRAD52UBE2N | |
| SCHEMBL15243340 | 0.84 | CACNA1H (0.53) | CACNA1HCACNA1BCACNA1CSMN1; SMN2BCHE | |
| SCHEMBL23731882 | 0.84 | CACNA1H (0.53) | CACNA1HCACNA1BCACNA1CSMN1; SMN2BCHE | |
| SCHEMBL15584671 | 0.84 | CACNA1H (0.53) | CACNA1HCACNA1BCACNA1CSMN1; SMN2BCHE | |
| SCHEMBL19494664 | 0.84 | CACNA1H (0.55) | CACNA1HCACNA1BCACNA1CSMN1; SMN2BCHE | |
| SCHEMBL30103105 | 0.84 | CACNA1H (0.53) | CACNA1HCACNA1BCACNA1CSMN1; SMN2BCHE | |
| SCHEMBL12635714 | 0.83 | EGLN1 (0.54) | CACNA1HCACNA1BCACNA1CSMN1; SMN2CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122195-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| US-12195458-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2025-01-14 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230116403-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2023-04-13 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| EP-4069694-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | Storm Therapeutics Ltd (GB) | 2022-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122195-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | CACNA1H 4798/4885CACNA1B 4866/4885CACNA1C 4844/4885 |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | CACNA1H 4798/4885CACNA1B 4866/4885CACNA1C 4844/4885 |
| US-20230116403-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | CACNA1H 4798/4885CACNA1B 4866/4885CACNA1C 4844/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | CACNA1H 4798/4885CACNA1B 4866/4885CACNA1C 4844/4885 |
| US-12195458-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | CACNA1H 4798/4885CACNA1B 4866/4885CACNA1C 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.